原文发表于美国时间2024-7-8
英国一家生物科技公司Immunocore控股公司（代码：IMCR）在今日上午有2000份将于2024年10月18日到期的看跌期权成交，平均成交价为2.00美元。成交时的全国最佳买卖报价（NBBO）分别是1.65美元/3.40美元。
期权交易时，Immunocore控股公司股票的交易价格区间为37.55美元至37.75美元。
Immunocore控股公司看跌期权的delta值为32，因此期权交易相当于6万4000股Immunocore控股公司的股票。
Immunocore控股公司在今天上午有2500份将于2024年10月18日到期的看跌期权的未平仓合约，目前尚不清楚这是平仓交易还是开仓交易。
Immunocore控股公司股票目前的交易价格为每股37.90美元。Immunocore控股公司股票的52周高点为每股37.95美元，52周低点为每股37.07美元。
资料来源：IBKR交易者工作站。过去的表现并不预示未来的结果。
—
懂行的，选盈透！
这篇文章已被翻译成中文。原英文作者Jeff Praissman。如英文版本和中文版本之间有任何不一致，以英文版本为准。该文章中的分析仅为提供信息，不是也不应该被视为推销或招揽购买任何证券。文章中讨论的一般市场活动、行业或领域趋势、或其它基于广泛的经济或政治条件的内容，不应被解释为研究结果或投资建议。讨论中提及包括的特定证券、商品、货币、或其它产品均不构成IB推荐购买，出售或持有此类投资的建议。本材料不是也不意图针对个别客户的特定财务条件、投资目标或要求。在根据本材料采取行动之前，您应该考虑是否适合您的具体情况，并在必要时寻求专业建议。
DISCLOSURE: INTERACTIVE BROKERS
The analysis in this material is provided for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation by IBKR to buy, sell or hold such investments. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Interactive Brokers LLC, its affiliates, or its employees.
Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.
In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
DISCLOSURE: OPTIONS TRADING
Options involve risk and are not suitable for all investors. For more information read the “Characteristics and Risks of Standardized Options” also known as the options disclosure document (ODD). To receive a copy of the ODD call 312-542-6901.Multiple leg strategies, including spreads, will incur multiple commission charges.
